DE69722426T3 - Isobutylgaba und dessen derivate zur schmerzbehandlung - Google Patents
Isobutylgaba und dessen derivate zur schmerzbehandlung Download PDFInfo
- Publication number
- DE69722426T3 DE69722426T3 DE1997622426 DE69722426T DE69722426T3 DE 69722426 T3 DE69722426 T3 DE 69722426T3 DE 1997622426 DE1997622426 DE 1997622426 DE 69722426 T DE69722426 T DE 69722426T DE 69722426 T3 DE69722426 T3 DE 69722426T3
- Authority
- DE
- Germany
- Prior art keywords
- pain
- use according
- isobutylgaba
- gabapentin
- surgery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 45
- 230000036407 pain Effects 0.000 title claims abstract description 43
- 238000011282 treatment Methods 0.000 title claims description 8
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 17
- 208000004550 Postoperative Pain Diseases 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 7
- 208000004296 neuralgia Diseases 0.000 claims description 5
- 208000021722 neuropathic pain Diseases 0.000 claims description 5
- 206010065390 Inflammatory pain Diseases 0.000 claims description 4
- 208000004983 Phantom Limb Diseases 0.000 claims description 3
- 206010056238 Phantom pain Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 206010058019 Cancer Pain Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 13
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract description 6
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 abstract description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- 235000013922 glutamic acid Nutrition 0.000 abstract 1
- 239000004220 glutamic acid Substances 0.000 abstract 1
- 208000004454 Hyperalgesia Diseases 0.000 description 63
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 60
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 35
- 229960002870 gabapentin Drugs 0.000 description 29
- 241001465754 Metazoa Species 0.000 description 28
- 238000001356 surgical procedure Methods 0.000 description 24
- 206010053552 allodynia Diseases 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 20
- 210000002683 foot Anatomy 0.000 description 20
- 241000700159 Rattus Species 0.000 description 18
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 17
- 229960005181 morphine Drugs 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 229920001525 carrageenan Polymers 0.000 description 14
- 235000010418 carrageenan Nutrition 0.000 description 14
- 230000003447 ipsilateral effect Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 239000000679 carrageenan Substances 0.000 description 13
- 229940113118 carrageenan Drugs 0.000 description 13
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 13
- 208000035154 Hyperesthesia Diseases 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 238000011161 development Methods 0.000 description 8
- 210000000548 hind-foot Anatomy 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000012353 t test Methods 0.000 description 8
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- AYXYPKUFHZROOJ-UHFFFAOYSA-N 3-(azaniumylmethyl)-5-methylhexanoate Chemical compound CC(C)CC(CN)CC(O)=O AYXYPKUFHZROOJ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000013222 sprague-dawley male rat Methods 0.000 description 3
- FJJYHTVHBVXEEQ-UHFFFAOYSA-N 2,2-dimethylpropanal Chemical compound CC(C)(C)C=O FJJYHTVHBVXEEQ-UHFFFAOYSA-N 0.000 description 2
- 208000001387 Causalgia Diseases 0.000 description 2
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 229920005372 Plexiglas® Polymers 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 230000003070 anti-hyperalgesia Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000003195 fascia Anatomy 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 1
- HGINADPHJQTSKN-UHFFFAOYSA-M 3-ethoxy-3-oxopropanoate Chemical compound CCOC(=O)CC([O-])=O HGINADPHJQTSKN-UHFFFAOYSA-M 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000006000 Knoevenagel condensation reaction Methods 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 206010068106 Occipital neuralgia Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- LINDOXZENKYESA-UHFFFAOYSA-N TMG Natural products CNC(N)=NC LINDOXZENKYESA-UHFFFAOYSA-N 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- -1 aliphatic nitro compounds Chemical class 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003574 anti-allodynic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 108010056028 auromycin Proteins 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003461 brachial plexus Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- MNBODUCODDEXEE-UHFFFAOYSA-N ethyl 4,4-dimethylpent-2-enoate Chemical compound CCOC(=O)C=CC(C)(C)C MNBODUCODDEXEE-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000011542 limb amputation Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- OBLVSONFNRLRIQ-UHFFFAOYSA-N lithium;ethyl acetate Chemical compound [Li+].CCOC([CH2-])=O OBLVSONFNRLRIQ-UHFFFAOYSA-N 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 201000005518 mononeuropathy Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940063650 terramycin Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 238000009901 transfer hydrogenation reaction Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2233796P | 1996-07-24 | 1996-07-24 | |
| US22337P | 1996-07-24 | ||
| EP97932617.0A EP0934061B3 (en) | 1996-07-24 | 1997-07-16 | Isobutylgaba and its derivatives for the treatment of pain |
| PCT/US1997/012390 WO1998003167A1 (en) | 1996-07-24 | 1997-07-16 | Isobutylgaba and its derivatives for the treatment of pain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE69722426D1 DE69722426D1 (de) | 2003-07-03 |
| DE69722426T2 DE69722426T2 (de) | 2004-04-08 |
| DE69722426T3 true DE69722426T3 (de) | 2015-05-07 |
Family
ID=21809080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE1997622426 Expired - Lifetime DE69722426T3 (de) | 1996-07-24 | 1997-07-16 | Isobutylgaba und dessen derivate zur schmerzbehandlung |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | USRE41920E1 (enExample) |
| EP (1) | EP0934061B3 (enExample) |
| JP (1) | JP3693258B2 (enExample) |
| KR (1) | KR100491282B1 (enExample) |
| CN (1) | CN1094757C (enExample) |
| AT (1) | ATE241351T1 (enExample) |
| AU (1) | AU714980B2 (enExample) |
| BR (1) | BR9710536A (enExample) |
| CA (1) | CA2255652C (enExample) |
| CU (1) | CU22850A3 (enExample) |
| DE (1) | DE69722426T3 (enExample) |
| DK (1) | DK0934061T6 (enExample) |
| ES (1) | ES2200184T7 (enExample) |
| HR (1) | HRP970387A2 (enExample) |
| HU (2) | HU228426B1 (enExample) |
| IL (1) | IL126999A (enExample) |
| NO (2) | NO325822B1 (enExample) |
| NZ (1) | NZ332762A (enExample) |
| PL (1) | PL189872B1 (enExample) |
| PT (1) | PT934061E (enExample) |
| SI (1) | SI0934061T1 (enExample) |
| WO (1) | WO1998003167A1 (enExample) |
| ZA (1) | ZA976562B (enExample) |
Families Citing this family (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP980342A2 (en) * | 1997-06-25 | 1999-02-28 | Warner Lambert Co | Anti-inflammatory method |
| US6329429B1 (en) | 1997-06-25 | 2001-12-11 | Warner-Lambert Company | Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases |
| WO1999012537A1 (en) * | 1997-09-08 | 1999-03-18 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| EP0974351A3 (en) * | 1998-04-24 | 2000-12-13 | Jouveinal | Medicament for preventing and treating gastrointestinal damage |
| ID27724A (id) * | 1998-05-15 | 2001-04-26 | Warner Lambert Co | Penstabil sediaan parmasi dari turunan-turunan asam gamma-aminobutira dan proses pembuatannya |
| US6680343B1 (en) | 1998-07-09 | 2004-01-20 | Warner-Lambert Comapny | Treatment of renal colic with GABA analogs |
| US20030045500A1 (en) * | 1998-07-09 | 2003-03-06 | Leslie Magnus | Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles |
| CA2332931C (en) * | 1998-07-09 | 2007-04-24 | Warner-Lambert Company | The treatment of renal colic with gaba analogs |
| JP2002520276A (ja) * | 1998-07-09 | 2002-07-09 | ワーナー−ランバート・カンパニー | Ｇａｂａ類縁体及び鬱血除去剤を含んでなる洞頭痛の痛みを軽減するための組成物 |
| CA2332929C (en) * | 1998-07-09 | 2005-05-31 | Warner-Lambert Company | Pharmaceutical composition containing gaba analogs and an antiviral agent to treat shingles |
| US6992109B1 (en) * | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
| WO2000067742A2 (en) * | 1999-05-05 | 2000-11-16 | Warner-Lambert Company | Use of gaba analogues for the modulation of substance p |
| US7164034B2 (en) * | 1999-06-10 | 2007-01-16 | Pfizer Inc. | Alpha2delta ligands for fibromyalgia and other disorders |
| US20080207755A1 (en) * | 2000-05-31 | 2008-08-28 | Pfizer Inc | Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders |
| CN1310872C (zh) * | 1999-06-10 | 2007-04-18 | 沃尼尔·朗伯公司 | 单和双取代的3－丙基－γ－氨基丁酸 |
| EP1840117A1 (en) * | 1999-06-10 | 2007-10-03 | Warner-Lambert Company LLC | Mono- and disubstituted 3-propyl gamma-aminobutyric acids |
| IL139073A0 (en) * | 1999-10-21 | 2001-11-25 | Pfizer | Treatment of neuropathy |
| ME00921B (me) * | 2000-01-27 | 2012-06-20 | Warner Lambert Co | Asimetrična sinteza pregabalina |
| US6687187B2 (en) * | 2000-08-11 | 2004-02-03 | Phonak Ag | Method for directional location and locating system |
| CA2356829A1 (en) * | 2000-09-22 | 2002-03-22 | Warner-Lambert Company | Method for treating asthma using pregabalin |
| US6620829B2 (en) * | 2000-10-17 | 2003-09-16 | Warner-Lambert Company | Method of treating noninflammatory cartilage damage |
| GB2368579A (en) * | 2000-10-31 | 2002-05-08 | Parke Davis & Co Ltd | Azole pharmaceutical agents |
| ATE327744T1 (de) * | 2001-03-20 | 2006-06-15 | Sanol Arznei Schwarz Gmbh | Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz |
| ATE228358T1 (de) * | 2001-03-21 | 2002-12-15 | Sanol Arznei Schwarz Gmbh | Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phantomschmerzen |
| US7420002B2 (en) * | 2001-06-11 | 2008-09-02 | Xenoport | Amino acid conjugates providing for sustained systemic concentrations of GABA analogues |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7232924B2 (en) * | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| WO2002100347A2 (en) * | 2001-06-11 | 2002-12-19 | Xenoport, Inc. | Prodrugs of gaba analogs, compositions and uses thereof |
| US7186855B2 (en) * | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US6818787B2 (en) * | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| IL160523A0 (en) * | 2001-09-03 | 2004-07-25 | Newron Pharm Spa | PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN alpha-AMINOAMIDE AND ITS ANALGESIC USE |
| US6927036B2 (en) * | 2002-02-19 | 2005-08-09 | Xero Port, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| AU2003243180A1 (en) * | 2002-05-17 | 2003-12-12 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| GB0219024D0 (en) * | 2002-08-15 | 2002-09-25 | Pfizer Ltd | Synergistic combinations |
| US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| US20040162351A1 (en) * | 2002-12-11 | 2004-08-19 | Gallop Mark A. | Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity |
| AU2003297927A1 (en) * | 2002-12-11 | 2004-06-30 | Xenoport, Inc. | Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof |
| KR100709159B1 (ko) * | 2002-12-13 | 2007-04-19 | 워너-램버트 캄파니 엘엘씨 | 섬유근육통 및 기타 관련 장애를 위한 가바펜틴 유사체 |
| AU2003303040B2 (en) * | 2002-12-13 | 2009-04-23 | Warner-Lambert Company Llc | Pregabalin derivatives for the treatment of fibromyalgia and other disorders |
| CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| KR20070091049A (ko) | 2002-12-13 | 2007-09-06 | 워너-램버트 캄파니 엘엘씨 | 하부요로증상을 치료하기 위한 알파-2-델타 리간드 |
| KR100845932B1 (ko) * | 2002-12-13 | 2008-07-11 | 워너-램버트 캄파니 엘엘씨 | 섬유근육통 및 기타 관련 질환의 치료를 위한 프레가발린및 그의 유도체 |
| US20080318908A1 (en) * | 2002-12-17 | 2008-12-25 | Trustees Of Tufts College | Use of gaba and gabab agonists |
| RU2320369C2 (ru) | 2003-09-12 | 2008-03-27 | Пфайзер Инк. | Комбинации, содержащие альфа-2-дельта лиганды и ингибиторы обратного захвата серотонина/норадреналина |
| WO2005027850A2 (en) * | 2003-09-17 | 2005-03-31 | Xenoport, Inc. | Treating or preventing restless legs syndrome using prodrugs of gaba analogs |
| RU2412162C2 (ru) | 2003-10-14 | 2011-02-20 | Ксенопорт, Инк. | Кристаллическая форма аналога y-аминомасляной кислоты |
| AU2004294714B2 (en) * | 2003-12-02 | 2009-12-10 | Ucb Pharma Gmbh | Novel use of peptide compounds for treating central neuropathic pain |
| JP2007528893A (ja) * | 2004-03-12 | 2007-10-18 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | Ｃ１対称ビスホスフィンリガンド及びプレガバリンの不斉合成におけるそれらの使用 |
| US20100256179A1 (en) * | 2004-03-26 | 2010-10-07 | Ucb Pharma Gmbh | Combination therapy for pain in painful diabetic neuropathy |
| US20070042969A1 (en) * | 2004-03-26 | 2007-02-22 | Srz Properties, Inc. | Combination therapy for pain in painful diabetic neuropathy |
| ATE405572T1 (de) * | 2004-04-01 | 2008-09-15 | Warner Lambert Co | Herstellung von p-chirogenen phospholanen und deren verwendung in der asymmetrischen synthese |
| JP2007532607A (ja) | 2004-04-16 | 2007-11-15 | シュバルツ ファルマ アクチェンゲゼルシャフト | 慢性頭痛の予防及び治療のためのペプチド化合物の使用 |
| EP1604655A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in trigeminal neuralgia |
| CN102102114B (zh) | 2004-06-21 | 2013-08-14 | 沃尼尔·朗伯有限责任公司 | 普瑞巴林和相关化合物的制备 |
| JP2008510758A (ja) * | 2004-08-27 | 2008-04-10 | シュヴァルツ・ファーマ・アーゲー | 骨肉腫の痛み、化学療法誘発性及びヌクレオシド誘発性の痛みを治療するためのペプチド化合物の新規使用 |
| RU2440112C2 (ru) | 2004-11-04 | 2012-01-20 | Ксенопорт, Инк. | Пероральная дозированная форма габапентина замедленного высвобождения |
| EP1879854B1 (en) | 2005-05-10 | 2011-09-07 | Teva Pharmaceutical Industries Ltd | Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid |
| WO2006122258A1 (en) * | 2005-05-10 | 2006-11-16 | Teva Pharmaceutical Industries Ltd. | Method for the preparation of pregabalin and salts thereof |
| WO2006124609A2 (en) * | 2005-05-16 | 2006-11-23 | Joseph Johnson | Methods and compositions for treating arg |
| CN101180045A (zh) * | 2005-05-20 | 2008-05-14 | 辉瑞有限公司 | 非甾类抗炎药物与α-2-δ配体的协同组合 |
| US20070048372A1 (en) * | 2005-08-18 | 2007-03-01 | Srz Properties, Inc. | Method for treating non-inflammatory osteoarthritic pain |
| US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
| EP1754476A1 (en) * | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
| US7563923B2 (en) | 2005-09-19 | 2009-07-21 | Teva Pharmaceutical Industries Ltd. | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin |
| EP2019817A2 (en) * | 2006-05-24 | 2009-02-04 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation of r-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof |
| JP5443981B2 (ja) | 2006-06-15 | 2014-03-19 | ウーツェーベー ファルマ ゲーエムベーハー | 相乗的抗痙攣効果を有する医薬組成物 |
| BRPI0803092A2 (pt) * | 2007-03-22 | 2011-08-30 | Teva Pharma | sìntese de (s)-(+)-3-(aminometil)-5-metil ácido hexanóico, (s)-pregabalina |
| KR20090101462A (ko) * | 2007-10-03 | 2009-09-28 | 테바 파마슈티컬 인더스트리즈 리미티드 | 프레가발린-4-엘리미네이트, 프레가발린 5-엘리미네이트, 기준 마커 및 표준물로서의 이들의 용도, 및 이들을 낮은 수준으로 함유하는 프레가발린의 제조 방법 |
| US20100087525A1 (en) * | 2008-06-23 | 2010-04-08 | Lilach Hedvati | Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester |
| WO2010070593A2 (en) | 2008-12-19 | 2010-06-24 | Pfizer Ireland Pharmaceuticals | Malonate esters |
| EP2400989B1 (en) | 2009-02-24 | 2016-08-10 | Nektar Therapeutics | Gabapentin-peg conjugates |
| JP2012526793A (ja) | 2009-05-15 | 2012-11-01 | レッドエックス ファーマ リミテッド | 酸化還元薬物誘導体 |
| WO2010150221A1 (en) | 2009-06-25 | 2010-12-29 | Wockhardt Research Centre | Taste masked pharmaceutical compositions of pregabalin |
| US20110130454A1 (en) * | 2009-11-24 | 2011-06-02 | Xenoport, Inc. | Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof |
| US20110124705A1 (en) * | 2009-11-24 | 2011-05-26 | Xenoport, Inc. | Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof |
| ES2758554T3 (es) | 2009-12-08 | 2020-05-05 | Univ Case Western Reserve | Aminoácidos gama para tratamiento de trastornos oculares |
| HU230031B1 (hu) | 2010-03-01 | 2015-05-28 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény |
| WO2011141923A2 (en) | 2010-05-14 | 2011-11-17 | Lupin Limited | Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin |
| IN2012MN02923A (enExample) | 2010-06-01 | 2015-06-05 | Rubicon Res Private Ltd | |
| WO2012025861A1 (en) | 2010-08-23 | 2012-03-01 | Pfizer Manufacturing Ireland | Process for the preparation of ( s ) - 3 - cyano - 5 - methylhexanoic acid derivatives adn of pregabalin |
| US8466297B2 (en) | 2010-11-01 | 2013-06-18 | Milan Soukup | Manufacturing process for (S)-Pregabalin |
| WO2012059797A1 (en) | 2010-11-04 | 2012-05-10 | Lupin Limited | Process for synthesis of (s) - pregabalin |
| AU2013213769A1 (en) | 2012-01-30 | 2014-08-21 | Sun Pharmaceutical Industries Limited | Gastroretentive tablets |
| US20140378545A1 (en) | 2012-01-30 | 2014-12-25 | Ranbaxy Laboratories Limited | Pregabalin gr tablets |
| CN102966602B (zh) * | 2012-12-14 | 2015-08-05 | 江苏海鸥冷却塔股份有限公司 | 一种冷却塔节能导流风筒 |
| ES2961655T3 (es) | 2013-01-18 | 2024-03-13 | Kemphys Ltd | Medicamento para tratamiento de enfermedad neuropática |
| ES2630128T3 (es) | 2013-03-27 | 2017-08-18 | Pfizer Ireland Pharmaceuticals | Procedimiento e intermedios para la preparación de pregabalina |
| CN107920987A (zh) | 2015-05-26 | 2018-04-17 | 艾萨·欧蒂迪 | 控制延缓释放普瑞巴林 |
| GB201617380D0 (en) * | 2016-10-13 | 2016-11-30 | St George's Hospital Medical School | Treatment for Osteoarthritis |
| KR102039345B1 (ko) | 2017-02-01 | 2019-11-01 | 지엘팜텍주식회사 | 프레가발린 함유 고팽윤성 서방성 삼중정제 |
| KR102039344B1 (ko) | 2017-02-01 | 2019-11-01 | 지엘팜텍주식회사 | 프레가발린 함유 경구용 서방성 삼중정제 |
| GB201703123D0 (en) | 2017-02-27 | 2017-04-12 | St George's Hospital Medical School | Biomarkers |
| AU2019271799B2 (en) | 2018-05-14 | 2023-10-12 | Xgene Pharmaceutical Inc. | Crystalline forms of 1-(acyloxy)-alkyl carbamate drug conjugates of naproxen and pregabalin |
| CN108926573A (zh) * | 2018-07-03 | 2018-12-04 | 泓博元生命科技（深圳）有限公司 | 一种可降低尿酸指数的nadh组合物及其制备方法及应用 |
| KR20200056719A (ko) | 2018-11-15 | 2020-05-25 | 단국대학교 천안캠퍼스 산학협력단 | 가바펜티노이드를 포함하는, 척수손상 개체의 신경재생 또는 신경회복을 위한 조성물 |
| JP2023511370A (ja) | 2020-01-22 | 2023-03-17 | シーロス セラピューティクス， インコーポレイテッド | Ｎｍｄａ拮抗薬の副作用の低減 |
| WO2021191108A1 (en) | 2020-03-23 | 2021-09-30 | Plus Vitech, S.L. | Treatment or prevention of acute organ damage induced by viral infection with a nk1 inhibitor and/or a gabapentinoid |
| WO2022038131A1 (en) | 2020-08-19 | 2022-02-24 | Plus Vitech, S.L. | Method for the prediction of progression or prognosis of the response of a subject suffering from acute organ damage |
| WO2022157527A1 (en) | 2021-01-22 | 2022-07-28 | Egis Gyógyszergyár Zrt. | Topical formulation containing dispersed pregabalin |
| HU231397B1 (hu) | 2021-01-22 | 2023-06-28 | Egis Gyógyszergyár Zrt. | Pregabalint tartalmazó topikális gyógyszerkészítmény |
| WO2022234110A1 (en) | 2021-05-07 | 2022-11-10 | Plus Vitech, S.L. | Gamma-aminobutyric acid derivatives for use in cancer therapy |
| WO2022243430A1 (en) | 2021-05-20 | 2022-11-24 | Plus Vitech, S.L. | Treatment of acne |
| WO2022253748A1 (en) | 2021-06-03 | 2022-12-08 | Plus Vitech, S.L. | Combinations for the treatment of hpv |
Family Cites Families (156)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH449645A (de) | 1963-07-09 | 1968-01-15 | Ciba Geigy | Verfahren zur Herstellung neuer Aminosäuren |
| JPS4940460Y2 (enExample) | 1971-05-19 | 1974-11-06 | ||
| DE2460891C2 (de) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US4087544A (en) | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
| US4123438A (en) | 1975-03-05 | 1978-10-31 | Stamicarbon, B.V. | Process for preparing 2-pyrrolidones |
| NZ194348A (en) | 1979-07-26 | 1982-09-14 | Merrell Toraude & Co | Fluorinated methyl-beta-alanine derivatives and pharmaceutical compositions |
| US4322440A (en) | 1980-06-25 | 1982-03-30 | New York University | Anticonvulsive compositions and method of treating convulsive disorders |
| US4513135A (en) | 1982-03-05 | 1985-04-23 | Eli Lilly And Company | Diaryl-pyrazine derivatives affecting GABA binding |
| DK373383A (da) | 1982-08-20 | 1984-02-21 | Midit | Fremgangsmaade til fremstilling af omega-aminosyrederivater |
| US4479005A (en) | 1982-12-16 | 1984-10-23 | The Dow Chemical Company | Selective preparation of isomers and enantiomers of cyclopropane carboxylic acids |
| EP0133795B1 (en) | 1983-08-01 | 1989-01-18 | THE McLEAN HOSPITAL CORPORATION | Gaba esters and gaba analogue esters |
| US5051448A (en) | 1984-07-24 | 1991-09-24 | The Mclean Hospital Corporation | GABA esters and GABA analog esters |
| GB8425872D0 (en) | 1984-10-12 | 1984-11-21 | Ciba Geigy Ag | Chemical compounds |
| DK170473B1 (da) | 1985-06-20 | 1995-09-11 | Daiichi Seiyaku Co | S(-)-pyridobenzoxazinforbindelser |
| US4956388A (en) | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
| JP2535001B2 (ja) | 1987-01-13 | 1996-09-18 | ダイセル化学工業株式会社 | Ｎ−アルキル化アミノ酸エステルの製法 |
| JPH07116064B2 (ja) | 1987-07-21 | 1995-12-13 | 三菱化学株式会社 | 分離剤 |
| US4908210A (en) | 1988-10-28 | 1990-03-13 | Eastman Kodak Company | Lactylic salt tablet formulations and tablets |
| GB8911017D0 (en) | 1989-05-13 | 1989-06-28 | Ciba Geigy Ag | Substituted aminoalkylphosphinic acids |
| DE3928183A1 (de) | 1989-08-25 | 1991-02-28 | Goedecke Ag | Lactamfreie cyclische aminosaeuren |
| GB8921304D0 (en) | 1989-09-20 | 1989-11-08 | Wyeth John & Brother Ltd | New method of treatment and heterocyclic compounds used therein |
| US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
| US5084479A (en) | 1990-01-02 | 1992-01-28 | Warner-Lambert Company | Novel methods for treating neurodegenerative diseases |
| US5025035A (en) | 1990-10-12 | 1991-06-18 | Warner-Lambert Company | Method of treating depression |
| AU9137091A (en) * | 1990-11-27 | 1992-06-25 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
| US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
| WO1992014443A1 (en) | 1991-02-20 | 1992-09-03 | Warner-Lambert Company | Microsphere-in-oil emulsion |
| DK204791D0 (da) | 1991-12-20 | 1991-12-20 | Novo Nordisk As | Hidtil ukendt farmaceutisk praeparat |
| CA2134674C (en) | 1992-05-20 | 2004-12-21 | Richard B. Silverman | Gaba and l-glutamic acid analogs for antiseizure treatment |
| GB9308430D0 (en) | 1993-04-23 | 1993-06-09 | Glaxo Group Ltd | Medicaments |
| US5492927A (en) | 1993-12-21 | 1996-02-20 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists to treat allergy |
| US5652216A (en) | 1994-05-26 | 1997-07-29 | Novo Nordisk A/S | Pharmaceutical preparation |
| US5792796A (en) | 1994-07-27 | 1998-08-11 | Warner-Lambert Company | Methods for treating anxiety and panic |
| NZ290050A (en) | 1994-07-27 | 1999-08-30 | Warner Lambert Co | Treatment of anxiety with gabapentin |
| GB9420784D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Group Ltd | Medicaments |
| US5767117A (en) | 1994-11-18 | 1998-06-16 | The General Hospital Corporation | Method for treating vascular headaches |
| WO1996021661A1 (en) | 1995-01-12 | 1996-07-18 | Glaxo Group Limited | Piperidine derivatives having tachykinin antagonist activity |
| JPH11501016A (ja) | 1995-02-28 | 1999-01-26 | ハー・ルンドベック・アクチェゼルスカベット | ４−アミノテトラヒドロベンズイソオキサゾール又は−イソチアゾール化合物 |
| US5510381A (en) | 1995-05-15 | 1996-04-23 | Warner-Lambert Company | Method of treatment of mania and bipolar disorder |
| US5616793A (en) | 1995-06-02 | 1997-04-01 | Warner-Lambert Company | Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid |
| US5637767A (en) | 1995-06-07 | 1997-06-10 | Warner-Lambert Company | Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid |
| ES2176668T3 (es) | 1996-02-07 | 2002-12-01 | Warner Lambert Co | Aminoacidos ciclicos novedosos como agentes farmaceuticos. |
| JP2000506862A (ja) | 1996-03-14 | 2000-06-06 | ワーナー―ランバート・コンパニー | 医薬としての新規な架橋環状アミノ酸 |
| TR199801807T2 (xx) | 1996-03-14 | 1998-12-21 | Warner-Lambert Company | Farmas�tik maddeler olarak yeni ikame edilmi� siklik amino asitler. |
| US20020077461A1 (en) | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
| US6372792B1 (en) | 1996-04-26 | 2002-04-16 | Guy Chouinard | Method for treating anxiety, anxiety disorders and insomnia |
| CA2255651A1 (en) | 1996-06-26 | 1997-12-31 | Warner-Lambert Company | Use of a tachykinin antagonist for the manufacture of a medicament for the treatment of emesis |
| SE9603408D0 (sv) | 1996-09-18 | 1996-09-18 | Astra Ab | Medical use |
| HRP980342A2 (en) | 1997-06-25 | 1999-02-28 | Warner Lambert Co | Anti-inflammatory method |
| US6329429B1 (en) | 1997-06-25 | 2001-12-11 | Warner-Lambert Company | Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases |
| US6194459B1 (en) | 1997-08-19 | 2001-02-27 | Warner-Lambert Company | Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotors stimulants |
| US6127418A (en) | 1997-08-20 | 2000-10-03 | Warner-Lambert Company | GABA analogs to prevent and treat gastrointestinal damage |
| WO1999008670A1 (en) | 1997-08-20 | 1999-02-25 | Guglietta, Antonio | Gaba analogs to prevent and treat gastrointestinal damage |
| WO1999012537A1 (en) | 1997-09-08 | 1999-03-18 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| JP2002508361A (ja) | 1997-12-16 | 2002-03-19 | ワーナー−ランバート・カンパニー | （（シクロ）アルキル置換）−γ−アミノ酪酸誘導体（＝ＧＡＢＡ類似体）、それらの製造および神経学的疾患の治療における使用 |
| BR9910494B1 (pt) | 1998-05-15 | 2011-11-01 | composições sólidas contendo derivados de ácido gama-aminobutìrico e processo para o seu preparo. | |
| ID27724A (id) | 1998-05-15 | 2001-04-26 | Warner Lambert Co | Penstabil sediaan parmasi dari turunan-turunan asam gamma-aminobutira dan proses pembuatannya |
| US20030045500A1 (en) | 1998-07-09 | 2003-03-06 | Leslie Magnus | Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles |
| ID27191A (id) | 1998-07-09 | 2001-03-08 | Warner Lambert Co | Metode untuk pengobatan insomnia |
| US6680343B1 (en) | 1998-07-09 | 2004-01-20 | Warner-Lambert Comapny | Treatment of renal colic with GABA analogs |
| WO2000002562A1 (en) | 1998-07-09 | 2000-01-20 | Warner-Lambert Company | Compositions comprising gaba analogs and caffeine |
| US6359005B1 (en) | 1998-10-16 | 2002-03-19 | Warner-Lambert Company | Method for the treatment of mania and bipolar disorder |
| AU3216600A (en) | 1999-03-10 | 2000-09-28 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| US6992109B1 (en) | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
| EP1180058A1 (en) | 1999-04-09 | 2002-02-20 | Warner-Lambert Company | Combinations of gaba analogs and tricyclic compounds to treat depression |
| CA2371395A1 (en) | 1999-06-02 | 2000-12-07 | Warner Lambert Company | Amino heterocycles useful as pharmaceutical agents |
| US7164034B2 (en) | 1999-06-10 | 2007-01-16 | Pfizer Inc. | Alpha2delta ligands for fibromyalgia and other disorders |
| US6642398B2 (en) | 1999-06-10 | 2003-11-04 | Warner-Lambert Company | Mono-and disubstituted 3-propyl gamma-aminobutyric acids |
| WO2001001983A1 (en) | 1999-07-02 | 2001-01-11 | Warner-Lambert Company | A synergistic combination: gabapentin and pregabalin |
| US7030119B1 (en) | 1999-07-16 | 2006-04-18 | Warner-Lambert Company | Method for treating chronic pain using MEK inhibitors |
| EP1214599A2 (en) | 1999-09-16 | 2002-06-19 | Warner-Lambert Company | Screening for alpha2delta-1 subunit binding ligands |
| AP2002002501A0 (en) | 1999-10-07 | 2002-06-30 | Warner Lambert Co | Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog. |
| ME00921B (me) | 2000-01-27 | 2012-06-20 | Warner Lambert Co | Asimetrična sinteza pregabalina |
| US20010036943A1 (en) | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| CA2408246A1 (en) | 2000-05-16 | 2001-11-22 | Warner-Lambert Company | Cell line for the expression of an .alpha.2.delta.2 calcium channel subunit |
| GB2365425A (en) | 2000-08-01 | 2002-02-20 | Parke Davis & Co Ltd | Alkyl amino acid derivatives useful as pharmaceutical agents |
| CA2356829A1 (en) | 2000-09-22 | 2002-03-22 | Warner-Lambert Company | Method for treating asthma using pregabalin |
| US6620829B2 (en) | 2000-10-17 | 2003-09-16 | Warner-Lambert Company | Method of treating noninflammatory cartilage damage |
| KR20030059290A (ko) | 2000-11-30 | 2003-07-07 | 화이자 프로덕츠 인코포레이티드 | Ｇａｂａ 작용제 및 소르비톨 데하이드로게나제 억제제의혼합물 |
| CN1477976A (zh) | 2000-11-30 | 2004-02-25 | �Ʒ� | Gaba激动剂与醛糖还原酶抑制剂的组合 |
| CA2428778A1 (en) | 2000-12-13 | 2002-06-20 | Warner-Lambert Company Llc | P-chirale bisphospholane ligands, their transition metal complexes |
| US20040002543A1 (en) | 2001-02-16 | 2004-01-01 | Leslie Magnus | Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain |
| EP1236720B1 (en) | 2001-02-28 | 2005-06-15 | Pfizer Products Inc. | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors |
| MXPA02001147A (es) | 2001-03-19 | 2004-04-21 | Warner Lambert Co | Sintesis de ligandos bisfosina no-c2-simetricos como catalizadores para la hidrogenacion asimetrica. |
| US7022678B2 (en) | 2001-03-30 | 2006-04-04 | Warner-Lambert Company | Pregabalin lactose conjugates |
| EP1247809A3 (en) | 2001-03-30 | 2003-12-17 | Pfizer Products Inc. | Triazine compounds useful as sorbitol dehydrogenase inhibitors |
| YU71403A (sh) | 2001-03-30 | 2006-05-25 | Pfizer Products Inc. | Piridazinoni kao inhibitori aldoza reduktaze |
| HUP0303808A2 (hu) | 2001-04-19 | 2004-03-01 | Warner-Lambert Company Llc | Kondenzált biciklusos vagy triciklusos aminosavak, aljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| AP1815A (en) | 2001-05-25 | 2008-01-04 | Warner Lambert Co | Liquid pharmaceutical composition. |
| US20030045449A1 (en) | 2001-08-15 | 2003-03-06 | Pfizer, Inc. | Pharmaceutical combinations for the treatment of neurodegenerative diseases |
| DE10203122A1 (de) | 2002-01-25 | 2003-07-31 | Gruenenthal Gmbh | Verfahren zur Herstellung von substituierten Acrylsäureestern bzw. deren Einsatz zur Herstellung von substituierten gamma-Aminosäuren |
| EP1469841A1 (en) | 2002-01-31 | 2004-10-27 | Warner-Lambert Company | Alpha 2 delta ligands to treat tinnitus |
| US6855724B2 (en) | 2002-04-08 | 2005-02-15 | Agouron Pharmaceuticals, Inc. | Tropane derivatives useful in therapy |
| US6713490B2 (en) | 2002-04-26 | 2004-03-30 | Pfizer, Inc. | 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists |
| US20030225149A1 (en) | 2002-04-30 | 2003-12-04 | Blazecka Peter G. | Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids |
| PL375090A1 (en) | 2002-06-27 | 2005-11-14 | Warner-Lambert Company Llc | Method of treating attention deficit hyperactivity disorder |
| ES2518940T3 (es) | 2002-07-08 | 2014-11-06 | Pfizer Products Inc. | Moduladores del receptor de glucocorticoides |
| US7053122B2 (en) | 2002-08-09 | 2006-05-30 | Pfizer Inc | Therapeutic use of aryl amino acid derivatives |
| US20040092522A1 (en) | 2002-08-15 | 2004-05-13 | Field Mark John | Synergistic combinations |
| US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| US7071339B2 (en) | 2002-08-29 | 2006-07-04 | Warner Lambert Company Llc | Process for preparing functionalized γ-butyrolactones from mucohalic acid |
| US7659305B2 (en) | 2002-10-31 | 2010-02-09 | Pfizer Inc. | Therapeutic proline derivatives |
| CA2508601A1 (en) | 2002-12-06 | 2004-06-24 | Warner-Lambert Company Llc | Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k |
| CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| KR100845932B1 (ko) | 2002-12-13 | 2008-07-11 | 워너-램버트 캄파니 엘엘씨 | 섬유근육통 및 기타 관련 질환의 치료를 위한 프레가발린및 그의 유도체 |
| US7572910B2 (en) | 2003-02-20 | 2009-08-11 | Pfizer, Inc. | Pyridazinone aldose reductase inhibitors |
| RU2005135454A (ru) | 2003-05-16 | 2006-06-27 | Пфайзер Продактс Инк. (Us) | Терапевтические комбинации атипичных нейролептиков с модуляторами гамк и/или противосудорожными препаратами |
| WO2004108708A1 (en) | 2003-06-05 | 2004-12-16 | Warner-Lambert Company Llc | 3-substituted indoles and derivatives thereof as therapeutic agents |
| CA2572324A1 (en) | 2003-07-02 | 2005-01-13 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
| UA86204C2 (uk) | 2003-09-03 | 2009-04-10 | Пфайзер Инк. | Сполуки бензімідазолону, які мають 5-нт4 рецепторну агоністичну активність |
| KR20060087560A (ko) | 2003-09-12 | 2006-08-02 | 워너-램버트 캄파니 엘엘씨 | 알파-2-델타 리간드 및 ｓｓｒｉ 및/또는 ｓｎｒｉ를포함하는 우울증 및 불안 장애 치료용 조합물 |
| RU2320369C2 (ru) | 2003-09-12 | 2008-03-27 | Пфайзер Инк. | Комбинации, содержащие альфа-2-дельта лиганды и ингибиторы обратного захвата серотонина/норадреналина |
| GB0322140D0 (en) | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
| WO2005030703A1 (en) | 2003-09-25 | 2005-04-07 | Warner-Lambert Company Llc | PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE α2δ- PROTEIN |
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| EP1543831A1 (en) | 2003-12-18 | 2005-06-22 | Pfizer GmbH Arzneimittelwerk Gödecke | Pregabalin composition |
| CA2553291A1 (en) | 2004-01-29 | 2005-09-09 | Pfizer Products Inc. | Combination of .gamma.-aminobutyric acid modulators and 5-ht1b receptor antagonists |
| GB0405200D0 (en) | 2004-03-08 | 2004-04-21 | Pfizer Ltd | Combinations comprising alpha-2-delta ligands |
| JP2007528893A (ja) | 2004-03-12 | 2007-10-18 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | Ｃ１対称ビスホスフィンリガンド及びプレガバリンの不斉合成におけるそれらの使用 |
| WO2005092895A2 (en) | 2004-03-29 | 2005-10-06 | Pfizer Japan Inc. | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists |
| ATE405572T1 (de) | 2004-04-01 | 2008-09-15 | Warner Lambert Co | Herstellung von p-chirogenen phospholanen und deren verwendung in der asymmetrischen synthese |
| ES2317209T3 (es) | 2004-04-07 | 2009-04-16 | Pfizer Inc. | Pirazolo(4,3-) pirimidinas. |
| UA82292C2 (uk) | 2004-04-14 | 2008-03-25 | Пфайзер Продактс Инк. | Спосіб стереоселективного біоперетворення аліфатичних динітрилів в ціанокарбонові кислоти (варіанти) |
| AU2005235248A1 (en) | 2004-04-20 | 2005-11-03 | Pfizer Products Inc. | Combinations comprising alpha-2-delta ligands and EP4 receptor antagonists |
| BRPI0510043A (pt) | 2004-04-20 | 2007-10-16 | Pfizer | método de tratamento de dor neuropática usando antagonista de receptor crth2 |
| WO2005102390A2 (en) | 2004-04-22 | 2005-11-03 | Pfizer Japan, Inc. | Combinations comprising alpha-2-delta ligands and nmda receptor antagonists |
| MXPA06012505A (es) | 2004-04-30 | 2006-12-15 | Warner Lambert Co | Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central. |
| AU2005254800B2 (en) | 2004-06-15 | 2010-12-09 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
| US7737163B2 (en) | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
| CN102102114B (zh) | 2004-06-21 | 2013-08-14 | 沃尼尔·朗伯有限责任公司 | 普瑞巴林和相关化合物的制备 |
| AU2005258911A1 (en) | 2004-06-29 | 2006-01-12 | Pfizer Products Inc. | Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3H`1,2,4!triazin-2-YL!-benzamide derivatives by deprotecting the hydroxyl-protected precursers |
| US20060003344A1 (en) | 2004-06-30 | 2006-01-05 | Pfizer Inc. | Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40 |
| WO2006008640A1 (en) | 2004-07-15 | 2006-01-26 | Pharmacia & Upjohn Company Llc | Non-aqueous suspension containing a drug having an unpleasant taste |
| WO2006011050A2 (en) | 2004-07-23 | 2006-02-02 | Pfizer Limited | Pyridine derivatives |
| GB0419849D0 (en) | 2004-09-07 | 2004-10-13 | Pfizer Ltd | Pharmaceutical combination |
| ATE417830T1 (de) | 2004-11-02 | 2009-01-15 | Pfizer | Sulfonylbenzimidazolderivate |
| CN101087771A (zh) | 2004-11-10 | 2007-12-12 | 辉瑞大药厂 | 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物 |
| US7122683B2 (en) | 2004-11-23 | 2006-10-17 | Pfizer Inc. | Amides useful as monoamine re-uptake inhibitors |
| BRPI0518693A2 (pt) | 2004-11-29 | 2008-12-02 | Warner Lambert Co | pirazol [3,4-b]piridinas e indazàis terapÊuticos, bem como composiÇço farmacÊutica e uso dos mesmos |
| GEP20094727B (en) | 2005-02-22 | 2009-07-10 | Pfizer | Oxyindole derivatives as 5ht4 receptor agonists |
| WO2006092692A1 (en) | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain |
| ATE443056T1 (de) | 2005-03-10 | 2009-10-15 | Pfizer | Substituierte n-sulfonylaminophenylethyl-2- phenoxyacetamidverbindungen |
| AP2007004157A0 (en) | 2005-03-17 | 2007-10-31 | Pfizer | N- (N-sulfonylaminomethyl) cyclo-propanecarboxamide derivatives useful for the treatment of pain |
| WO2006111856A1 (en) | 2005-04-20 | 2006-10-26 | Pfizer Limited | Pyrazole derivatives as progesterone receptor antagonists |
| AU2006238933B2 (en) | 2005-04-28 | 2011-12-01 | Pfizer Limited | Amino acid derivatives |
| CN101180045A (zh) | 2005-05-20 | 2008-05-14 | 辉瑞有限公司 | 非甾类抗炎药物与α-2-δ配体的协同组合 |
| CA2610354C (en) | 2005-05-31 | 2011-03-29 | Pfizer Inc. | Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists |
| NL2000281C2 (nl) | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Vaste farmaceutische samenstellingen die pregabaline bevatten. |
| NL2000284C2 (nl) | 2005-11-04 | 2007-09-28 | Pfizer Ltd | Pyrazine-derivaten. |
| PT1948615E (pt) | 2005-11-08 | 2012-02-03 | Pfizer Ltd | Derivados de pirazol úteis para o tratamento de doenças ginecológicas |
| CA2631535C (en) | 2005-12-02 | 2010-07-27 | Pfizer Limited | Spirocyclic quinazoline derivatives as pde7 inhibitors |
| CA2530904C (en) | 2005-12-20 | 2013-10-08 | John Marino | Pharmaceutical agents for the treatment of pain associated with spinal cord injury |
| BRPI0708671A2 (pt) | 2006-03-06 | 2011-06-07 | Pfizer Prod Inc | ligantes alfa-2-delta para sono não restaurador |
| GB0700786D0 (en) | 2007-01-15 | 2007-02-21 | Pfizer Ltd | Morpholine dopamine agonists for the treatment of pain |
| KR101107949B1 (ko) | 2007-02-02 | 2012-02-08 | 화이자 프로덕츠 인코포레이티드 | 트라이사이클릭 화합물 및 글루코코르티코이드 수용체 조절자로서의 이들의 용도 |
| WO2008132589A1 (en) | 2007-05-01 | 2008-11-06 | Pfizer Limited | Combinations comprising pregabalin |
-
1997
- 1997-07-16 AT AT97932617T patent/ATE241351T1/de active
- 1997-07-16 EP EP97932617.0A patent/EP0934061B3/en not_active Expired - Lifetime
- 1997-07-16 ES ES97932617.0T patent/ES2200184T7/es active Active
- 1997-07-16 BR BR9710536A patent/BR9710536A/pt not_active Application Discontinuation
- 1997-07-16 SI SI9730545T patent/SI0934061T1/xx unknown
- 1997-07-16 DE DE1997622426 patent/DE69722426T3/de not_active Expired - Lifetime
- 1997-07-16 US US11/983,750 patent/USRE41920E1/en not_active Expired - Lifetime
- 1997-07-16 KR KR10-1999-7000577A patent/KR100491282B1/ko not_active Expired - Lifetime
- 1997-07-16 CA CA002255652A patent/CA2255652C/en not_active Expired - Lifetime
- 1997-07-16 PT PT97932617T patent/PT934061E/pt unknown
- 1997-07-16 HU HU9904361A patent/HU228426B1/hu active Protection Beyond IP Right Term
- 1997-07-16 JP JP50706298A patent/JP3693258B2/ja not_active Expired - Lifetime
- 1997-07-16 PL PL97331325A patent/PL189872B1/pl unknown
- 1997-07-16 US US09/043,358 patent/US6001876A/en not_active Expired - Lifetime
- 1997-07-16 CN CN97196041A patent/CN1094757C/zh not_active Expired - Lifetime
- 1997-07-16 IL IL12699997A patent/IL126999A/en not_active IP Right Cessation
- 1997-07-16 AU AU36024/97A patent/AU714980B2/en not_active Expired
- 1997-07-16 DK DK97932617.0T patent/DK0934061T6/en active
- 1997-07-16 WO PCT/US1997/012390 patent/WO1998003167A1/en not_active Ceased
- 1997-07-16 NZ NZ332762A patent/NZ332762A/xx not_active IP Right Cessation
- 1997-07-17 HR HR60/022,337A patent/HRP970387A2/hr not_active Application Discontinuation
- 1997-07-23 ZA ZA9706562A patent/ZA976562B/xx unknown
-
1999
- 1999-01-22 NO NO19990279A patent/NO325822B1/no not_active IP Right Cessation
- 1999-01-22 CU CU1999008A patent/CU22850A3/es unknown
-
2008
- 2008-12-04 NO NO2008018C patent/NO2008018I2/no unknown
-
2013
- 2013-08-27 HU HUS1300046C patent/HUS1300046I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69722426T3 (de) | Isobutylgaba und dessen derivate zur schmerzbehandlung | |
| DE60100055T2 (de) | Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen | |
| EP1207868A1 (de) | Pharmazeutische tramadolsalze | |
| EP0267321A1 (de) | Ibuprofen enthaltendes Arzneimittel | |
| DE60106026T2 (de) | 2-arachidonylglycerol (2-ag)-ein hemmer des tumor nekrose faktors-alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungen | |
| DE69008853T2 (de) | Verwendung eines Derivates des 1,3,7-Trimethylxanthins zur Behandlung von Gedächtnisstörungen, intellektuellen Störungen im Alter, und bei der Alzheimerkrankheit. | |
| DE69328792T2 (de) | Behandlung von migräne | |
| DE69103624T2 (de) | Ipriflavone enthaltende pharmazeutische zubereitungen, verfahren zur herstellung und therapeutische verwendung. | |
| EP0132595B1 (de) | Tokolytisches Mittel | |
| DE19629802A1 (de) | Arzneimittel zur Behandlung von Neuropathien | |
| DE69426317T2 (de) | Verwendung von Beta-Naphthochinonderivaten zur Hemmung von Blutplättchen-Aggregation | |
| DE1617812A1 (de) | Verfahren zur Herstellung von endoanaesthetisch wirkenden Loesungen von Kava-Wirkstoffen | |
| EP1721613B1 (de) | Hesperidin zur Behandlung von Epilepsie | |
| DE2501649C3 (de) | Thiophen-2-carbonsäuresalz des Papaverins, Verfahren zu seiner Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| EP2066314B1 (de) | Verwendung von theogallin zur behandlung von mentalen konzentrationsleistungsstörungen, depression und demenz | |
| DE2908127A1 (de) | Verwendung von inhibitoren des abbaus von enkephalinen und endorphinen bei der bekaempfung von schmerzzustaenden sowie zur herstellung pharmazeutischer zubereitungen und arzneimittel | |
| EP0870499A1 (de) | Orale Anwendung von (+)-0-Demethyltramadol als Schmerzmittel | |
| DE2551962C3 (de) | Verwendung eines Extraktes aus verschiedenen Spezies von Helleborus | |
| EP1621201A1 (de) | Hesperidin zur Prophylaxe und Behandlung von Erkrankungen des zentralen Nervensystems, insbesondere Morbus Alzheimer, Morbus Parkinson, zur Therapie nach Schlaganfall sowie von chronischen Schmerzzuständen | |
| DE3522894A1 (de) | Verwendung von tergurid als geriatrikum | |
| DE69110807T2 (de) | Verfahren zur herstellung von equimolaren salzen von asparaginsäure und magnesium, magnesiumaspartatsalz nach diesem verfahren und ihre verwendung. | |
| EP2703002A1 (de) | Pflanzliche Extrakte aus der Nachtkerze (Oenothera biennis) zur Behandlung von Störungen des zentralen Nervensystems | |
| DE102011108116A1 (de) | Reserpin zur Behandlung von kognitiven Störungen des zentralen Nervensystems | |
| DE2836149A1 (de) | Arzneimittel zur behandlung von parkinsonismus | |
| DE10311921A1 (de) | Verwendung von Weihrauch zur Behandlung von zerebraler Ischämie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent | ||
| 8365 | Fully valid after opposition proceedings |